Clinical Research & Evidence

Multicenter randomized controlled trial of 354 adults diagnosed with IBS shows individual and group hypnotherapy produced adequate symptom relief in ~33–41% of patients at 3 months and ~41–50% at 12 months, compared with ~17% at 3 months and ~23% at 12 months in the educational supportive therapy control group. Demonstrates hypnotherapy's significantly superior and durable benefit.

In a systematic review and network meta-analysis of 41 randomized controlled trials including 4,072 adults diagnosed with IBS, gut-directed hypnotherapy reduced the likelihood of remaining symptomatic by ~33% compared with control interventions (RR 0.67, 95% CI 0.49–0.91).

In a randomized controlled trial of 74 adults with IBS, gut-directed hypnotherapy produced symptom improvement comparable to a low-FODMAP diet, with ≥20-mm symptom reduction in ~72% of patients at 6 weeks and durable benefit in ~74% at 6 months. Hypnotherapy demonstrated significantly greater reductions in anxiety and depression than diet alone. No added benefit from combining the two treatments.

In a randomized controlled trial of 54 adults with quiescent ulcerative colitis and a prior flare rate of ~1.3 per year, gut-directed hypnotherapy prolonged clinical remission, with 68% of hypnotherapy patients remaining relapse-free at 1 year, compared with 40% of attention-control patients. Mean delay to relapse: 78 additional days.

This randomized controlled trial analyzed 36 adults with ulcerative colitis to determine if gut-directed hypnotherapy could extend periods of disease remission. Patients receiving hypnotherapy reported significantly greater improvements in bowel-specific health and physical functioning at the 20-week follow-up compared to those in the standard support group. The statistical analysis confirmed a 95% certainty that these health gains were a direct result of the intervention rather than random chance.

25 adults with active UC randomly assigned to one 50-minute hypnosis session or control. After a single session, hypnosis reduced rectal mucosal release of substance P by 81%, histamine by 35%, and interleukin-13 by 53%. Serum IL-6 dropped by 53%. The only study measuring hypnotherapy's direct effect on biological markers of gut inflammation.

126 adults with functional dyspepsia randomly assigned to hypnotherapy, supportive therapy, or medication. Short-term symptom improvement: 59% for hypnotherapy vs. 41% supportive and 33% medical. Long-term (56 weeks): 73% improvement in the hypnotherapy group vs. 34% and 43% in the other groups. Quality of life improved significantly more with hypnotherapy. Critically, zero patients in the hypnotherapy group required medication during follow-up vs. 90% of the medical group. The hypnotherapy group visited their physician a median of 1 time vs. 4 in both other groups.

Gut-focused hypnotherapy, when delivered by trained therapists, has been shown to be highly effective in severe refractory functional gastrointestinal disorders.

The American Academy of Family Physicians reviewed the above RCT and recommended hypnotherapy for chronic functional dyspepsia. Zero patients in the hypnotherapy group dropped out because the treatment wasn't working — compared to 13 and 10 patients in the other groups.

University of Liverpool cardiovascular researchers synthesized evidence that hypnotherapy reduces anxiety and may therefore reduce cardiovascular disease risk. A meta-analysis of 17 trials found hypnosis patients reduced anxiety more than 84% of control participants. Multiple studies show hypnosis directly shifts the autonomic nervous system toward parasympathetic dominance — reducing sympathetic activation, lowering heart rate, and modulating HPA axis stress hormones. An RCT of 30 patients with mild essential hypertension found that 8 sessions of hypnosis reduced systolic and diastolic blood pressure significantly vs. standard care, with effects maintained at 6 and 12 months.

The average participant receiving hypnosis reduced anxiety more than about 79% of control participants. Hypnosis was more effective in reducing anxiety when combined with other psychological interventions than when used as a stand-alone treatment.

This randomized controlled rater-blind clinical trial compared 152 adults with mild-to-moderate depression to determine if clinical hypnotherapy was as effective as the gold-standard Cognitive Behavioral Therapy (CBT). After 20 sessions, the “treatment response” rate — meaning a symptom reduction of at least 50% — was 44.6% for the hypnotherapy group, much better in comparison to 38.5% for the CBT group. These figures demonstrate that hypnotherapy is a highly effective primary treatment for clinical depression. By outperforming the response rate of the current leading standard of care, this study establishes hypnotherapy as a validated, evidence-based alternative for the millions of patients who do not respond to traditional talk therapy.

Researchers screened 232 articles and identified 14 studies on hypnotherapy as a treatment for depression. The majority found hypnotherapy effective in reducing depressive symptoms. Several studies found hypnotherapy performed equal to or better than antidepressant medications in reducing symptoms and improving overall wellbeing.

In a randomized controlled trial of 98 adults with chronic depression, Cognitive Hypnotherapy outperformed CBT in reducing depressive symptoms, anxiety, and hopelessness at the end of a 16-week treatment period, maintained at both 6- and 12-month follow-ups. The hypnotherapy group showed 6%, 5%, and 8% greater reduction in depression, anxiety, and hopelessness respectively over and above the CBT group.

Dr. Assen Alladin of University of Calgary Medical School presents Cognitive Hypnotherapy — combining hypnosis with CBT — as comprehensive evidence-based treatment for clinical depression. The American Psychological Association considers this approach “probably efficacious” for depression treatment.

Meta-analysis of 6 studies with 391 participants found hypnotherapy produced large, statistically significant reductions in PTSD symptoms across all studies. The authors calculated it would require 290 non-significant studies to nullify these findings. Effects maintained at follow-ups ranging from 12 weeks to 2 years.

This meta-analysis synthesized data from 47 different sources, ultimately focusing on 6 high-quality experimental trials involving patients with Post-Traumatic Stress Disorder (PTSD). Researchers found that hypnosis-based treatments produced a “large effect” on symptom reduction, which actually increased over time, rising from an initial effect size of 1.17 to 1.58 at the one-year follow-up. This data confirms that hypnotherapy is not only an effective immediate intervention for PTSD but its benefits are exceptionally stable and durable over the long term. Note: In many PTSD studies, standard medications or talk therapies achieve effect sizes between 0.50 and 0.90. Seeing numbers consistently above 1.10 — and seeing them increase after sessions ended — suggests that hypnotherapy helps the brain “re-wire” its response to trauma permanently, rather than providing a temporary band-aid for symptoms.

This systematic review analyzed 60 publications to evaluate the utility of hypnotherapy in pediatric mental health. While the researchers noted a need for more large-scale trials, they found that hypnotherapy consistently reduced symptoms across a wide range of conditions, proving particularly effective for anxiety disorders, trauma-related issues, and procedure-related distress. The study concludes that because children have a naturally high capacity for imagination, hypnotherapy is a highly effective clinical tool for enhancing a child's internal coping mechanisms and positive adjustment. This review establishes hypnotherapy as a powerful, developmentally appropriate intervention that can significantly improve treatment outcomes when used alongside traditional therapies like CBT for children facing mental health challenges.

Meta-analysis of 85 controlled trials with 3,632 participants found hypnotic intervention produced meaningful pain relief across all pain outcomes. Patients with medium to high hypnotic suggestibility achieved clinically meaningful reductions in pain of 29–42%.

Systematic review and meta-analysis of 9 RCTs with 530 participants found hypnosis produced a moderate, statistically significant decrease in both pain intensity and pain interference. A dose-response effect was identified: treatments of 8 or more sessions produced significantly larger effects than shorter courses.

Fibromyalgia syndrome is a multifaceted, incapacitating pain condition characterized by widespread musculoskeletal pain, fatigue, non-restorative sleep, and cognitive dysfunction — and it is refractory to most conventional treatments. This narrative review synthesizes the available RCT and meta-analytic evidence and concludes that psychological interventions, particularly hypnotherapy, have been shown to be effective in the cognitive modulation of fibromyalgic pain. One included study found that at 6-month follow-up, the hypnotherapy group demonstrated 70% mean pain relief versus only 25% in the control group, along with significantly superior quality of life, energy levels, and restorative sleep. The authors conclude that hypnosis is a useful and safe adjunct for managing chronic pain and dysfunctional symptoms in fibromyalgia patients.

In this prospective, parallel, randomized, controlled, blindly-evaluated trial, 49 participants with fibromyalgia and moderate to severe chronic pain attended 8 weekly one-hour hypnotherapy sessions. Hypnosis significantly reduced pain scores at both post-intervention and 3-month follow-up. Beyond pain, hypnosis modulated both the sensory and affective dimensions of pain perception, reduced pain catastrophizing, improved anxiety and depression, improved sleep quality, and diminished the overall impact of fibromyalgia on daily life. No adverse events were observed. The authors conclude that clinical hypnosis is an effective and feasible tool for managing chronic pain and the full symptom burden of fibromyalgia.

In a randomized controlled study of 20 fibromyalgia patients, the hypnosis group received 10 weekly 60-minute face-to-face hypnotherapy sessions in addition to standard medical treatment and exercise. At 3-month follow-up, the hypnosis group showed statistically significant improvements in both pain scores (VAS) and Fibromyalgia Impact Questionnaire values compared to the control group (p < 0.001), while the control group showed no significant change. No side effects were reported.

In a controlled study, 40 patients with refractory fibromyalgia were randomly assigned to hypnotherapy or physical therapy for 12 weeks, with follow-up at 24 weeks. The hypnotherapy group showed significantly better outcomes in pain experience, fatigue on awakening, sleep pattern, and global assessment at both 12 and 24 weeks. Somatic and psychic discomfort scores decreased significantly in the hypnotherapy group. The authors conclude that hypnotherapy may be useful in relieving symptoms in patients with refractory fibromyalgia — a population that has failed to respond to conventional treatment.

Meta-analyses performed with 20 RCTs with 1,250 patients. Results confirmed hypnosis as an effective non-pharmacological intervention. Authors found that hypnosis significantly reduced procedural anxiety and pain compared to standard care, and that hypnosis significantly reduces physiological stress markers like heart rate and blood pressure.

A joint guideline from the Society for Integrative Oncology and the American Society of Clinical Oncology recommends that hypnosis may be offered to people with cancer to reduce anxiety during diagnostic and treatment procedures (benefits outweigh harms; intermediate-quality evidence; moderate strength of recommendation). The recommendation draws on nine randomized trials published between 2005 and 2021, with 50 to 201 participants each. Benefit was clearest when hypnosis was applied to a specific procedure, such as central venous port implantation. In one trial of 69 patients having a capsaicin patch applied for post-treatment neuropathic pain, hypnosis and music both reduced anxiety during the procedure, and hypnosis was superior at reducing anxiety afterward. The guideline concludes that hypnosis offers benefit with minimal risk of adverse effects. The recommendation is specific to procedural anxiety, not anxiety in general.

A recent open-access review by a Geneva palliative care physician who is also a hypnotherapist, covering anxiety, procedural pain, fatigue, hot flushes, nausea and palliative care. Procedural and surgical pain is the best-supported use: the Society for Integrative Oncology–ASCO guideline recommends hypnosis for procedural or surgical pain in adults with cancer, based on five RCTs of intermediate quality. In an RCT of 95 breast cancer patients after treatment, an 8-week self-hypnosis and self-care group reduced emotional distress and improved insomnia, with benefits sustained at one year. A review of adverse events in hypnosis trials found no serious adverse events. The author notes that most trials are small, that quality was not formally assessed, and that hypnosis is not yet standard care outside procedural and surgical pain.

Meta-analysis of 20 studies of children and adults with cancer. Hypnosis had a significant immediate effect on anxiety (Hedges' g 0.70–1.41), and the effect was sustained at follow-up (g 0.61–2.77). Hypnosis delivered by a therapist worked significantly better than self-hypnosis. The effect sizes vary widely and the analysis included non-randomized designs, so this is best read as consistent evidence of benefit rather than a precise estimate.

In a randomized trial of 95 women with a range of cancers who had completed treatment, an 8-week group program combining self-hypnosis and self-care improved fatigue, sleep, emotional distress and cognitive functioning compared with a wait-list control. A one-year follow-up of the same trial found that most of these benefits were maintained. The follow-up is a continuation of the same study, not an independent replication, and the wait-list design does not separate the effect of hypnosis from the effect of attention.

The only dedicated systematic review of hypnosis for chemotherapy-induced nausea and vomiting. It identified six randomized controlled trials (206 patients), five of them in children. Meta-analysis found a large effect of hypnosis compared with treatment as usual, at least as large as cognitive-behavioral therapy, for anticipatory and chemotherapy-induced nausea and vomiting in children with cancer. The authors call for further high-quality trials with full descriptions of the hypnotic intervention.

A current review of hypnosis for symptoms in cancer treatment and at the end of life, including nausea and vomiting. It confirms that the 2007 review remains the most recent systematic review of hypnosis for chemotherapy-induced nausea, and notes that the adult evidence is thin: a four-arm trial of 67 adults undergoing bone marrow transplantation found no significant difference in nausea or vomiting between hypnosis and the comparison groups. Hypnosis here is best understood as a low-risk adjunct to antiemetic medication, not a replacement for it.

In a randomized controlled trial of 200 women undergoing excisional breast biopsy or lumpectomy, a single 15-minute hypnosis session within an hour of surgery was compared with an attention control of nondirected empathic listening. The hypnosis group needed less propofol and lidocaine during surgery, and reported less pain, nausea, fatigue, discomfort and emotional upset at discharge. On 0–100 scales (lower is better), hypnosis vs. control: pain intensity 22.4 vs. 47.8, nausea 6.6 vs. 25.5, fatigue 29.5 vs. 54.2, emotional upset 8.7 vs. 33.5. These are surgical, not chemotherapy, outcomes. Surgery ran about 11 minutes shorter, lowering costs by roughly $773 per patient. Patients could not be blinded to their group, a limitation inherent to hypnosis research.

In a randomized trial of 50 terminally ill cancer patients, one group received standard medical and psychological care and the other received the same care plus weekly hypnosis sessions with a therapist for four weeks. At the end of the intervention, the hypnosis group had significantly better overall quality of life and lower anxiety and depression. The trial is small, and because the comparison was standard care alone, it can't separate the effect of hypnosis from the effect of extra attention.

A Canadian pilot trial of people receiving palliative care at home near the end of life, using personalized, pre-recorded hypnosis and music sessions of about 20 minutes, compared with a delayed-intervention control. A 2026 systematic review rated it at low risk of bias and reported improvements in symptom scores and distress (distress effect size −0.69). The trial was small: 40 people were enrolled and about 30 completed it. It was not limited to cancer, and the sessions were recorded rather than delivered live, so it shows feasibility and early benefit, not proof.

A review of 27 studies (12 randomized trials, 15 pilots) of psychotherapy delivered by trained mental health professionals in palliative and hospice care. Four studies tested hypnotherapy: one small, low-bias randomized trial reported reduced distress, and two lower-quality pilots reported improvements in symptoms, anxiety, depression and sleep. By contrast, cognitive-behavioral therapy and dignity therapy mostly showed no significant benefit. The authors single out hypnotherapy as a priority for larger randomized trials. The review was not preregistered and counted only practitioners with formal psychotherapy training.

A systematic search of five databases for randomized trials of hypnosis for fatigue, sleep disturbance, pain, appetite loss and dyspnea in people with cancer at the end of life found no eligible trials. The authors conclude that hypnosis has not yet been rigorously tested for these symptoms in this population, and they set out how future studies could be done. It is an evidence gap, not evidence of no effect.

Researchers reviewed 60 published studies across a range of psychiatric conditions. Children are more easily hypnotized than adults. The review found hypnotherapy particularly effective for anxiety disorders, and confirmed existing evidence for its effectiveness in pediatric asthma, chronic and acute pain, and distress related to cancer treatment procedures.

This randomized controlled trial enrolled 100 children (ages 8–18) with functional nausea to compare the efficacy of gut-directed hypnotherapy against standard medical care. At one year, 57% of the hypnotherapy group achieved the primary outcome of “adequate relief” of nausea, compared to 40% in the medical treatment group. These results suggest that hypnotherapy is a superior and more durable intervention for pediatric functional nausea than conventional drug therapies.

Systematic review of 24 controlled trials and prospective studies found that 58.3% of included studies reported hypnosis to be beneficial for sleep. This positive finding held up in subgroup analysis restricted to lower-bias studies.

In a 5-year follow-up study of 36 patients with chronic, self-sustaining parasomnias — including children as young as 6 — all participants received just 1 or 2 hypnotherapy sessions and were then tracked by questionnaire over 5 years. At 1-month follow-up, 45.4% were symptom-free or much improved. Remarkably, this improvement held: 42.2% remained improved at 18 months and 40.5% at the 5-year mark. The authors conclude that 1 or 2 sessions of hypnotherapy may be an efficient first-line therapy for patients with certain parasomnias — an unusually strong outcome-to-effort ratio in clinical sleep medicine.

In a multicenter randomized controlled trial of 95 adults with elevated perceived stress, 5 weekly group hypnotherapy sessions reduced reported stress intensity by 21.2 points on a 100-point scale at 5 weeks. At 5 weeks, 95.5% of the hypnotherapy group reported their main therapeutic goal was at least partially achieved, compared to 27.9% in the control group. The effect held at 12-week follow-up. Improvements were also seen in depression, self-efficacy, and quality of life.

60 participants received a single 30-minute hypnosis session in which a “safety anchor” was established as a post-hypnotic cue. The safety anchor group reported significantly lower stress immediately after the stress task, and fewer negative thoughts during recovery. This is unusually compelling because it shows a clinically meaningful result from a single session with effects lasting at least a week. It also demonstrates that standard hypnotic suggestibility is not a prerequisite for benefit.

Cochrane systematic review of 9 randomized controlled trials with 2,954 women found that women who received hypnosis training for childbirth were significantly less likely to use pharmacological pain relief during labor. Hypnosis-trained women also reported higher satisfaction with their pain management. No adverse effects on mothers or infants identified across any included studies.

In a randomized controlled trial of 187 postmenopausal women experiencing at least 7 hot flashes per day, clinical hypnosis produced a 74% reduction in hot flash frequency compared to 17% in the structured attention control group at 12 weeks. Hot flash scores (frequency × severity) declined by 80% in the hypnosis group.

In a randomized controlled trial of 60 female university students with premenstrual syndrome, three weekly group hypnotherapy sessions produced significantly lower scores for depression, stress, and anxiety compared to an untreated control group at 3-month follow-up. Depression scores dropped from 7.97 to 3.40 in the hypnotherapy group vs. essentially unchanged in controls. Stress scores dropped from 9.70 to 4.63 vs. unchanged in controls. No adverse effects observed.